Wilms’ tumor 1 (WT1) may be a broader target of interest as it is overexpressed in the majority of patients with AML and MDS, and also to significantly lesser degrees in healthy tissue [127,128,129,130]. This evidence concerns the gene WT1 and acute myeloid leukemia.